Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

118 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Combination of aprepitant, palonosetron and dexamethasone as antiemetic prophylaxis in lung cancer patients receiving multiple cycles of cisplatin-based chemotherapy.
Longo F, Mansueto G, Lapadula V, Stumbo L, Del Bene G, Adua D, De Filippis L, Bonizzoni E, Quadrini S. Longo F, et al. Among authors: bonizzoni e. Int J Clin Pract. 2012 Aug;66(8):753-757. doi: 10.1111/j.1742-1241.2012.02969.x. Epub 2012 Jul 2. Int J Clin Pract. 2012. PMID: 22805267 Free PMC article.
Netupitant/palonosetron (NEPA) and dexamethasone for prevention of emesis in breast cancer patients receiving adjuvant anthracycline plus cyclophosphamide: a multi-cycle, phase II study.
Caputo R, Cazzaniga ME, Sbrana A, Torrisi R, Paris I, Giordano M, Montesarchio V, Guarneri V, Amaducci L, Bilancia D, Cilenti G, Fabi A, Collovà E, Schirone A, Bonizzoni E, Celio L, De Placido S, De Laurentiis M. Caputo R, et al. Among authors: bonizzoni e. BMC Cancer. 2020 Mar 19;20(1):232. doi: 10.1186/s12885-020-6707-9. BMC Cancer. 2020. PMID: 32188417 Free PMC article. Clinical Trial.
Dexamethasone-Sparing Regimens with Oral Netupitant and Palonosetron for the Prevention of Emesis Caused by High-Dose Cisplatin: A Randomized Noninferiority Study.
Celio L, Cortinovis D, Cogoni AA, Cavanna L, Martelli O, Carnio S, Collovà E, Bertolini F, Petrelli F, Cassano A, Chiari R, Zanelli F, Pisconti S, Vittimberga I, Letizia A, Misino A, Gernone A, Bonizzoni E, Pilotto S, De Placido S, Bria E. Celio L, et al. Among authors: bonizzoni e. Oncologist. 2021 Oct;26(10):e1854-e1861. doi: 10.1002/onco.13851. Epub 2021 Jun 18. Oncologist. 2021. PMID: 34101934 Free PMC article. Clinical Trial.
Efficacy and safety of netupitant/palonosetron combination (NEPA) in preventing nausea and vomiting in non-Hodgkin's lymphoma patients undergoing to chemomobilization before autologous stem cell transplantation.
Di Renzo N, Musso M, Scimè R, Cupri A, Perrone T, De Risi C, Pastore D, Guarini A, Mengarelli A, Benedetti F, Mazza P, Capria S, Chiusolo P, Cupelli L, Federico V, Bozzoli V, Messa AR, Matera R, Seripa D, Codega P, Bonizzoni E, Specchia G. Di Renzo N, et al. Among authors: bonizzoni e. Support Care Cancer. 2022 Feb;30(2):1521-1527. doi: 10.1007/s00520-021-06495-0. Epub 2021 Sep 17. Support Care Cancer. 2022. PMID: 34533630 Free PMC article. Clinical Trial.
Evaluating the impact of chemotherapy-induced nausea and vomiting on daily functioning in patients receiving dexamethasone-sparing antiemetic regimens with NEPA (netupitant/palonosetron) in the cisplatin setting: results from a randomized phase 3 study.
Celio L, Cortinovis D, Cogoni AA, Cavanna L, Martelli O, Carnio S, Collovà E, Bertolini F, Petrelli F, Cassano A, Chiari R, Zanelli F, Pisconti S, Vittimberga I, Letizia A, Misino A, Gernone A, Bonizzoni E, Pilotto S, De Placido S, Bria E. Celio L, et al. Among authors: bonizzoni e. BMC Cancer. 2022 Aug 24;22(1):915. doi: 10.1186/s12885-022-10018-3. BMC Cancer. 2022. PMID: 35999527 Free PMC article. Clinical Trial.
Exploratory analysis of the effect of a dexamethasone-sparing regimen for prophylaxis of cisplatin-induced emesis on food intake (LUNG-NEPA study).
Celio L, Cortinovis D, Cogoni AA, Cavanna L, Martelli O, Carnio S, Collovà E, Bertolini F, Petrelli F, Cassano A, Chiari R, Zanelli F, Pisconti S, Vittimberga I, Letizia A, Misino A, Gernone A, Bonizzoni E, Pilotto S, De Placido S, Bria E. Celio L, et al. Among authors: bonizzoni e. Sci Rep. 2023 Jan 23;13(1):1257. doi: 10.1038/s41598-023-28464-9. Sci Rep. 2023. PMID: 36690734 Free PMC article. Clinical Trial.
Palonosetron plus single-dose dexamethasone for the prevention of nausea and vomiting in women receiving anthracycline/cyclophosphamide-containing chemotherapy: meta-analysis of individual patient data examining the effect of age on outcome in two phase III trials.
Celio L, Bonizzoni E, Bajetta E, Sebastiani S, Perrone T, Aapro MS. Celio L, et al. Among authors: bonizzoni e. Support Care Cancer. 2013 Feb;21(2):565-73. doi: 10.1007/s00520-012-1558-9. Epub 2012 Aug 8. Support Care Cancer. 2013. PMID: 22869054 Free PMC article.
Should clinicians always administer dexamethasone beyond 24 h after chemotherapy to control delayed nausea and vomiting caused by moderately emetogenic regimens? Insight from the re-evaluation of two randomized studies.
Celio L, Bonizzoni E, De Braud F, Agustoni F, Aapro M. Celio L, et al. Among authors: bonizzoni e. Support Care Cancer. 2016 Mar;24(3):1025-34. doi: 10.1007/s00520-015-2871-x. Epub 2015 Aug 6. Support Care Cancer. 2016. PMID: 26245497 Free PMC article. Clinical Trial.
118 results